Development of new basal insulin peglispro (LY2605541) ends in a disappointing result

類似資料

• How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes
  著者:: Muñoz-Garach, Araceli, 等
  出版事項: (2016)
• Pharmacokinetics of the Long‐Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function
  著者:: Linnebjerg, Helle, 等
  出版事項: (2016)
• Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism
  著者:: Moore, Mary Courtney, 等
  出版事項: (2014)
• Open‐label, randomized study comparing basal insulin peglispro and insulin glargine, in combination with oral antihyperglycemic medications, in insulin‐naïve Asian patients with type 2 diabetes
  著者:: Hirose, Takahisa, 等
  出版事項: (2017)
• A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes
  著者:: Bergenstal, Richard M., 等
  出版事項: (2012)